These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 21494621)

  • 21. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.
    Drexler HG; Gignac SM; von Wasielewski R; Werner M; Dirks WG
    Leukemia; 2000 Sep; 14(9):1533-59. PubMed ID: 10994999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ALK-positive diffuse large B-cell lymphoma.
    Bubała H; Małdyk J; Włodarska I; Sońta-Jakimczyk D; Szczepański T
    Pediatr Blood Cancer; 2006 May; 46(5):649-53. PubMed ID: 15852431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors.
    Ceribelli M; Kelly PN; Shaffer AL; Wright GW; Xiao W; Yang Y; Mathews Griner LA; Guha R; Shinn P; Keller JM; Liu D; Patel PR; Ferrer M; Joshi S; Nerle S; Sandy P; Normant E; Thomas CJ; Staudt LM
    Proc Natl Acad Sci U S A; 2014 Aug; 111(31):11365-70. PubMed ID: 25049379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
    Yamada T; Takeuchi S; Nakade J; Kita K; Nakagawa T; Nanjo S; Nakamura T; Matsumoto K; Soda M; Mano H; Uenaka T; Yano S
    Clin Cancer Res; 2012 Jul; 18(13):3592-602. PubMed ID: 22553343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
    Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J
    Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels.
    Duijkers FA; Gaal J; Meijerink JP; Admiraal P; Pieters R; de Krijger RR; van Noesel MM
    Cell Oncol (Dordr); 2011 Oct; 34(5):409-17. PubMed ID: 21625996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma.
    Redaelli S; Ceccon M; Antolini L; Rigolio R; Pirola A; Peronaci M; Gambacorti-Passerini C; Mologni L
    Oncotarget; 2016 Nov; 7(45):72886-72897. PubMed ID: 27662658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Arsenic trioxide inhibits anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma through targeting ALK-fusion oncoprotein.
    Yue LM; Chau D; Kwong YL; Tse E
    Br J Haematol; 2021 Sep; 194(6):1085-1090. PubMed ID: 34121173
    [No Abstract]   [Full Text] [Related]  

  • 29. Anaplastic lymphoma kinase: Role in cancer and therapy perspective.
    Zhao Z; Verma V; Zhang M
    Cancer Biol Ther; 2015; 16(12):1691-701. PubMed ID: 26529396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells.
    Wan W; Albom MS; Lu L; Quail MR; Becknell NC; Weinberg LR; Reddy DR; Holskin BP; Angeles TS; Underiner TL; Meyer SL; Hudkins RL; Dorsey BD; Ator MA; Ruggeri BA; Cheng M
    Blood; 2006 Feb; 107(4):1617-23. PubMed ID: 16254137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TrkA is a binding partner of NPM-ALK that promotes the survival of ALK
    Shi W; George SK; George B; Curry CV; Murzabdillaeva A; Alkan S; Amin HM
    Mol Oncol; 2017 Sep; 11(9):1189-1207. PubMed ID: 28557340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis.
    Ma Z; Cools J; Marynen P; Cui X; Siebert R; Gesk S; Schlegelberger B; Peeters B; De Wolf-Peeters C; Wlodarska I; Morris SW
    Blood; 2000 Mar; 95(6):2144-9. PubMed ID: 10706887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway.
    Bai RY; Ouyang T; Miething C; Morris SW; Peschel C; Duyster J
    Blood; 2000 Dec; 96(13):4319-27. PubMed ID: 11110708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
    Menichincheri M; Ardini E; Magnaghi P; Avanzi N; Banfi P; Bossi R; Buffa L; Canevari G; Ceriani L; Colombo M; Corti L; Donati D; Fasolini M; Felder E; Fiorelli C; Fiorentini F; Galvani A; Isacchi A; Borgia AL; Marchionni C; Nesi M; Orrenius C; Panzeri A; Pesenti E; Rusconi L; Saccardo MB; Vanotti E; Perrone E; Orsini P
    J Med Chem; 2016 Apr; 59(7):3392-408. PubMed ID: 27003761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma.
    Carpenter EL; Haglund EA; Mace EM; Deng D; Martinez D; Wood AC; Chow AK; Weiser DA; Belcastro LT; Winter C; Bresler SC; Vigny M; Mazot P; Asgharzadeh S; Seeger RC; Zhao H; Guo R; Christensen JG; Orange JS; Pawel BR; Lemmon MA; Mossé YP
    Oncogene; 2012 Nov; 31(46):4859-67. PubMed ID: 22266870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.
    Huang WS; Liu S; Zou D; Thomas M; Wang Y; Zhou T; Romero J; Kohlmann A; Li F; Qi J; Cai L; Dwight TA; Xu Y; Xu R; Dodd R; Toms A; Parillon L; Lu X; Anjum R; Zhang S; Wang F; Keats J; Wardwell SD; Ning Y; Xu Q; Moran LE; Mohemmad QK; Jang HG; Clackson T; Narasimhan NI; Rivera VM; Zhu X; Dalgarno D; Shakespeare WC
    J Med Chem; 2016 May; 59(10):4948-64. PubMed ID: 27144831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of Polo-like kinase 4 induces mitotic defects and DNA damage in diffuse large B-cell lymphoma.
    Zhao Y; Yang J; Liu J; Cai Y; Han Y; Hu S; Ren S; Zhou X; Wang X
    Cell Death Dis; 2021 Jun; 12(7):640. PubMed ID: 34162828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oncogene addiction and radiation oncology: effect of radiotherapy with photons and carbon ions in ALK-EML4 translocated NSCLC.
    Dai Y; Wei Q; Schwager C; Hanne J; Zhou C; Herfarth K; Rieken S; Lipson KE; Debus J; Abdollahi A
    Radiat Oncol; 2018 Jan; 13(1):1. PubMed ID: 29304828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death.
    Torossian A; Broin N; Frentzel J; Daugrois C; Gandarillas S; Saati TA; Lamant L; Brousset P; Giuriato S; Espinos E
    Haematologica; 2019 Jul; 104(7):1428-1439. PubMed ID: 30679328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cytomorphology and molecular characterization of CLTC-ALK rearrangement in 2 cases of ALK-positive diffuse large B-cell lymphoma with extensive bone marrow involvement].
    Choung HS; Kim HJ; Kim WS; Kim K; Kim SH
    Korean J Lab Med; 2008 Apr; 28(2):89-94. PubMed ID: 18458503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.